Atlas Venture Opportunity Fund II, L.P.
SEC CIK 1885327 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | 10% | 934.6K | $10.00M | — | 1 | 2022-12-12 | 2022-12-12 |
Most active insiders at DYN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Rhodes Jason P | Dir | — | $129.10M |
| 2 | Kersten Dirk | Dir | — | $38.57M |
| 3 | Cox John | CEO, Pres, Dir | — | $443.7K |
| 4 | Posner Brian S | Dir | $274.8K | — |
| 5 | Kerr Douglas | Chief Medical Off | — | $233.1K |
| 6 | Lucera Erick | CFO | — | $228.7K |
| 7 | Friedl-Naderer Johanna | Chief Commercial Off | — | $43.4K |
| 8 | Lubner David Charles | Dir | — | — |
Atlas Venture Opportunity Fund II, L.P. made no open-market trades at DYN in the last 12 months.
Transactions 1
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-14 | 2022-12-12 | DYN | Dyne Therapeutics, Inc. | Atlas Venture Opportunity Fund II, L.P. | 10% | P - Purchase | $10.70 | +934.6K | 934.6K | New | +$10.00M |
Purchase Sale Sale after option exercise All abbreviations